S1 Info - STARD-BLCM checklist

Section & Topic	No	Item	Reported on page #
TITLE OR ABSTRACT			
	1	Identification as a study of diagnostic accuracy, using at least one measure of accuracy (such as sensitivity, specificity, predictive values, or AUC) **and Bayesian latent class models**	1
ABSTRACT			
	2	Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts)	1
INTRODUCTION			
	3	Scientific and clinical background, including the intended use and clinical role of the **tests under evaluation**	1-2
	4	Study objectives and hypotheses, **such as estimation of diagnostic accuracy of the tests for a defined purpose through BLCM**	1-2
METHODS			
Study design	**5**	Whether data collection was planned before the **tests** were performed (prospective study) or after (retrospective study)	2
Participants	**6**	Eligibility criteria **and description of the source population**	2-3
	7	On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)	2-3
	8	Where and when potentially eligible participants were identified (setting, location and dates)	2-3
	9	Whether participants formed a consecutive, random or convenience series	2-3
Test methods	**10**	**Description of the tests under evaluation**, in sufficient detail to allow replication, **and/or cite references**	3
	11	Rationale for choosing the **tests under evaluation in relation to their purpose**	3
	12	Definition of and rationale for test positivity cut-offs or result categories of **the tests under evaluation**, distinguishing pre-specified from exploratory	3
	13	Whether clinical information was available to the performers or readers of **the tests under evaluation**	3
Analysis	**14a**	**BLCM model** for estimating measures of diagnostic accuracy	4, S2 info
	14b	**Definition and rationale of prior information and sensitivity analysis**	4, S2 info
	15	How indeterminate results **of the tests under evaluation** were handled	4
	16	How missing data **of the tests under evaluation** were handled	4
	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory	NA
	18	Intended sample size and how it was determined	3
RESULTS			
Participants	**19**	Flow of participants, using a diagram	NA
	20	Baseline demographic and clinical characteristics of participants	2-3
	21	**Not applicable: the distribution of the targeted conditions is unknown, hence the use of BLCM**	NA
	22	Time interval and any clinical interventions between **the tests under evaluation**	2-3
Test results	**23**	Cross tabulation of the **tests' results (or for continuous tests results their distribution by infection stage)**	S4 Info
	24	Estimates of diagnostic accuracy **under alternative prior specification** and their precision (such as 95% **credible/probability intervals**)	7, S6 Info
	25	Any adverse events from performing **the tests under evaluation**	NA
DISCUSSION			
	26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	7
	27	Implications for practice, including the intended use and clinical role of **the tests under evaluation in relevant settings (clinical, research, surveillance etc.)**	1, 2, 7, 8
OTHER INFORMATION			
	28	Registration number and name of registry	NA
	29	Where the full study protocol can be accessed	Fully included in method section
	30	Sources of funding and other support; role of funders	Funding section